This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
Merck to Buy Immunotherapy Developer Immune Design for $300M
by Zacks Equity Research
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
by Zacks Equity Research
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Why Is Immune Design (IMDZ) Up 15.8% Since Last Earnings Report?
by Zacks Equity Research
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
Immune Design (IMDZ) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Immune Design (IMDZ) delivered earnings and revenue surprises of 9.38% and -37.99%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Immune Design to Halt Cancer Vaccine Program, Shares Plunge
by Zacks Equity Research
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
Implied Volatility Surging for Immune Design (IMDZ) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Immune Design (IMDZ) stock based on the movements in the options market lately.
Immune Design (IMDZ) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss and beats revenue estimates in the second quarter of 2018.
Immune Design (IMDZ) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immune Design (IMDZ) delivered earnings and revenue surprises of 3.33% and 17.97%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
by Zacks Equity Research
During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .
Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?
by Zacks Equity Research
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immune Design Poised on Progress of Pipeline Candidates
by Zacks Equity Research
Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
Why Immune Design (IMDZ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Immune Design (IMDZ) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock
by Zacks Equity Research
Immune Design (IMDZ) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock
by Zacks Equity Research
Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
by Zacks Equity Research
Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.
Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock
by Zacks Equity Research
Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.
Immune Design's Sarcoma Candidate to Enter Phase III in 2018
by Zacks Equity Research
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.